Skip to contentO
Oramed Pharmaceuticals Inc.
O
ORMPOramed Pharmaceuticals Inc. Q1 2017 · 10-Q
Revenue$610.00K$610.00Kno prior Q1 2016 on file Net Income-$2.64M-$2.64MN/M vs Q1 2016 EPS Diluted$0.20$0.20−4.8% vs Q1 2016 Operating Income-$2,398,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR
Margins · derivedOperating margin-393.1%
Net margin-432.1%
ended Nov 30, 2016 · filed Jan 11, 2017 · 42 d after period end